These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26908458)

  • 21. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.
    Bloom JE; McNeel DG
    Oncotarget; 2016 Aug; 7(32):50997-51011. PubMed ID: 27276714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
    Kim S; Lee J; Jeon M; Nam SJ; Lee JE
    Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.
    Zhang J; Liang Q; Lei Y; Yao M; Li L; Gao X; Feng J; Zhang Y; Gao H; Liu DX; Lu J; Huang B
    Cancer Res; 2012 Sep; 72(17):4597-608. PubMed ID: 22787120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
    Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
    Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment.
    Suarez-Carmona M; Bourcy M; Lesage J; Leroi N; Syne L; Blacher S; Hubert P; Erpicum C; Foidart JM; Delvenne P; Birembaut P; Noël A; Polette M; Gilles C
    J Pathol; 2015 Aug; 236(4):491-504. PubMed ID: 25880038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B
    Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
    Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
    Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities.
    Su Y; Pogash TJ; Nguyen TD; Russo J
    Cancer Med; 2016 Mar; 5(3):558-73. PubMed ID: 26775583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition.
    Li X; Kong X; Huo Q; Guo H; Yan S; Yuan C; Moran MS; Shao C; Yang Q
    Cancer Sci; 2011 Jun; 102(6):1151-7. PubMed ID: 21371176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ARF1 and ARF6 are dispensable for Crk-dependent epithelial-mesenchymal-like transitions.
    Lamorte L; Park M
    Anticancer Res; 2003; 23(3A):2085-92. PubMed ID: 12894582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia.
    Ren T; Zhang W; Liu X; Zhao H; Zhang J; Zhang J; Li X; Zhang Y; Bu X; Shi M; Yao L; Su J
    J Pathol; 2014 Dec; 234(4):526-37. PubMed ID: 25130389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling.
    Jung SY; Yi JY; Kim MH; Song KH; Kang SM; Ahn J; Hwang SG; Nam KY; Song JY
    Oncol Rep; 2015 Nov; 34(5):2731-7. PubMed ID: 26351897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epicatechin-3-gallate reverses TGF-β1-induced epithelial-to-mesenchymal transition and inhibits cell invasion and protease activities in human lung cancer cells.
    Huang SF; Horng CT; Hsieh YS; Hsieh YH; Chu SC; Chen PN
    Food Chem Toxicol; 2016 Aug; 94():1-10. PubMed ID: 27224248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.
    Okada T; Sinha S; Esposito I; Schiavon G; López-Lago MA; Su W; Pratilas CA; Abele C; Hernandez JM; Ohara M; Okada M; Viale A; Heguy A; Socci ND; Sapino A; Seshan VE; Long S; Inghirami G; Rosen N; Giancotti FG
    Nat Cell Biol; 2015 Jan; 17(1):81-94. PubMed ID: 25531777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
    Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
    Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.